整理 | GLP1减重宝典内容团队 肥胖，作为全球范围内的重大公共卫生问题，近年来已成为全球许多国家面临的严峻挑战。肥胖的发生是由多种因素的复杂交织所引起 的，包括遗传、神经生物学因素、饮食习惯以及"致肥环境"的影响。现代社会中，快节奏的生活方式、饮食结构的变化、缺乏运动等因 素都加剧了肥胖问题。 世界卫生组织（WHO）将肥胖视为一种慢性、复发性的疾病，全球目前已有超过10亿人受到肥胖困扰，且这一数字仍在持续上升。根据 2024年的数据显示，肥胖导致的非传染性疾病死亡人数已高达370万，占全球非传染性疾病死亡总数的12%。预计到2030年，肥胖相关 的健康负担将达到每年3万亿美元，严重影响国家的卫生支出。 ▍ GLP-1疗法的革命性突破 最初用于治疗糖尿病的GLP-1类药物（胰高糖素样肽-1），近年来已经成为应对全球肥胖危机的重要疗法。GLP-1药物通过促进饱腹 感、抑制食欲等机制，帮助患者控制体重，同时对糖尿病和其他代谢性疾病也具有治疗作用。GLP-1药物的推出，不仅为肥胖患者提供 了新的治疗选择，也为传统的生活方式干预和药物治疗提供了重要补充。 随着多个国家的监管机构批准GLP-1疗法，WHO发布了关于肥 ...

2025年，全球"药王"宝座完成了一次引人瞩目的更迭，礼来的"明星单品"替尔泊肽以365.07亿美元的骄 人战绩强势登顶，成为新一届全球药物销售冠军。 GLP-1的崛起与"药王"更迭 全球药品百强榜从来不只是商业销售的成绩单，它还是映照行业未来的"风向标"。正因如此，"药王"之 争向来就备受瞩目。 紧随其后的，是其老对手诺和诺德的司美格鲁肽，2025年销售额达到361亿美元，以4亿美元的微小差距 位居次席。 替尔泊肽和司美格鲁肽同属GLP-1受体激动剂家族。它们的双双登顶，不仅是GLP-1类药物的一次重大 胜利，也标志着代谢性疾病的治疗进入了一个全新时代。其核心适应症——2型糖尿病和肥胖症，正影 响着全球数亿患者，市场潜力巨大。特别是近年来减肥市场的爆发性增长，成为了推动这场"药王"更迭 的关键引擎。 在这一场激烈的角逐中，替尔泊肽的崛起速度尤其令人称奇，从2022年获批上市，到2025年问鼎"药 王"，全程仅用了不到四年，刷新了行业纪录。 在许多人看来，它的成功关键在于其创新的双靶点作用机制。然而鲜有人知的是，如同众多传奇药物一 样，替尔泊肽的登顶绝非偶然。它的背后，是一段曾被长期忽视的靶点逆袭之路，是科研 ...

Core Viewpoint - Semaglutide, marketed as Ozempic, is emerging as a revolutionary drug with the potential to treat multiple diseases beyond diabetes, including obesity, cardiovascular issues, and even neurodegenerative diseases like Alzheimer's [3][4][9]. Group 1: Drug Efficacy and Benefits - Semaglutide has shown the ability to reduce the risk of heart attacks and strokes by nearly 20% in patients [3]. - The drug has been linked to improvements in mental health, including reductions in depression and anxiety [3]. - In a three-year trial, semaglutide was found to lower the risk of kidney failure and death in diabetic patients [3]. - Research indicates that liraglutide, another GLP-1 drug, can reduce brain atrophy in Alzheimer's patients and slow cognitive decline [3][12]. Group 2: Mechanisms of Action - The exact mechanisms by which semaglutide treats various diseases remain unclear, but it is believed to influence brain reward pathways and inflammation [4][11]. - Semaglutide mimics the natural hormone GLP-1, which helps lower blood sugar levels and affects appetite regulation by signaling the pancreas to release insulin and slowing gastric emptying [7][19]. - The drug has anti-inflammatory properties, which may contribute to its effectiveness in treating conditions like cardiovascular diseases and other inflammation-related disorders [9][11]. Group 3: Market Impact and Usage - Semaglutide is marketed at a high price point, approximately $1,300 per month, yet it has gained significant traction, with around 25,000 new users in the U.S. each week [7]. - The drug's weight loss effects are substantial, with patients typically losing about 15% of their body weight after one year of treatment [7]. - The potential for semaglutide to improve fertility and overall health outcomes is being recognized, particularly in patients with high body mass index [8][9].

Group 1 - The company expects the product Glatiramer to launch in the US market in the first quarter of 2026, marking it as a significant peptide formulation following Liraglutide [1][2] - Other products, including SemaGlutide, are planned to be launched in an orderly manner in 2026, with a goal of introducing 1-2 new products to the US market annually [2] - The innovative drug HY3003 has completed preclinical preparations and is expected to apply for clinical trials in the third quarter of 2026, while also advancing domestic Phase I clinical trials [2] Group 2 - The company signed a substantial sales order for GLP-1 raw materials amounting to 180 million yuan, which represents approximately 30.5% of the expected revenue for 2024 [2] - The company is accelerating the construction of its CRDMO (Contract Research, Development, and Manufacturing Organization) service team and has identified the small nucleic acid field as a second growth curve, leveraging global certified production capacity to expand customized peptide and small nucleic acid businesses [2]

Core Viewpoint - The article discusses the growing interest and developments in GLP-1 medications, which are used for weight loss and diabetes management, highlighting their mechanism of action and the potential benefits they offer in these areas [14]. Group 1: GLP-1 Medications Overview - GLP-1 (Glucagon-like peptide-1) is a hormone produced by intestinal L cells, classified as an incretin, which enhances insulin secretion in a glucose-dependent manner and suppresses glucagon secretion [14]. - GLP-1 receptor agonists are a new class of diabetes medications that also aid in weight loss by delaying gastric emptying and reducing appetite through central mechanisms [14]. Group 2: Industry Engagement and Community - The "GLP-1 Club" has established a network of hundreds of professionals, creating a comprehensive expert database that covers various sectors of the GLP-1 industry, making it a primary choice for industry insights [10]. - The article mentions a weight loss challenge involving two individuals in Zhengzhou, who entered a "bet agreement" with their employer to lose weight, reflecting the increasing societal focus on weight management [4].

Core Viewpoint - The article discusses the challenges and new perspectives in the treatment of resistant hypertension, highlighting the potential of GLP-1/GIP receptor agonists in managing blood pressure for patients who do not respond to traditional medications [6][12]. Group 1: Resistant Hypertension - Resistant hypertension is defined as a condition where patients cannot achieve effective blood pressure control despite using five or more antihypertensive medications at maximum doses [6]. - This condition significantly increases the risk of cardiovascular and renal complications, yet treatment options remain limited [6]. Group 2: Case Study and Treatment Progress - A case study of a 71-year-old female patient illustrates the challenges of managing resistant hypertension. Despite being on eight antihypertensive medications, her blood pressure remained uncontrolled, with systolic readings exceeding 200 mmHg [7][10]. - The patient began treatment with liraglutide in 2013, which reduced her systolic blood pressure from 206 mmHg to 160 mmHg over six years [8]. - In 2019, the treatment was switched to dulaglutide, and in 2023 to terzepatide, resulting in a further reduction of systolic blood pressure to 135 mmHg, indicating the effectiveness of GLP-1/GIP receptor agonists [9][10]. Group 3: Mechanisms of Action - GLP-1/GIP receptors are widely distributed in the hypothalamus, carotid body, vascular endothelium, and kidneys. Animal studies suggest these agonists may lower blood pressure by inhibiting sympathetic nervous system activity, improving endothelial dysfunction, and/or reducing vascular remodeling [12]. - The case study suggests that GLP-1/GIP receptor agonists may have broader applications in blood pressure control, particularly for resistant hypertension, indicating a need for further exploration of their mechanisms [12].

Core Viewpoint - Obesity is becoming one of the most systemic public health risks globally, significantly increasing the incidence of non-communicable diseases such as type 2 diabetes and cardiovascular diseases, thus straining healthcare systems and financial resources [4] Group 1: GLP-1 Receptor Agonists - GLP-1 receptor agonists have evolved from diabetes treatment drugs to key tools in managing obesity and its complications, showing clear weight loss and cardiometabolic benefits in multiple randomized controlled trials [4] - A recent study published in The Lancet Diabetes & Endocrinology assessed the potential population size for GLP-1 receptor agonists in obesity treatment, integrating health survey data from 99 countries covering over 810,000 non-pregnant adults aged 25 to 64 [5] - The study defined eligibility for GLP-1 receptor agonists based on BMI thresholds, with a general standard of BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with hypertension and/or diabetes, adjusting thresholds for Southeast Asia, East Asia, and South Asia due to increased metabolic risks at lower BMI levels [5] Group 2: Potential Patient Population - Approximately 27.0% of adults globally meet the medical criteria for GLP-1 receptor agonists for weight management, translating to a potential population size of about 799 million people, indicating that one in four adults may be medically suitable for this treatment [6] - The proportion of individuals who should use GLP-1 receptor agonists varies significantly by income level, with high-income countries at 41.8% and low-income countries at 11.7%, while nearly four-fifths of the potential patient population is concentrated in middle-income countries [6] - The regional distribution shows the highest applicability in Europe and North America at 42.8%, while Southeast Asia, East Asia, and South Asia, despite a lower applicability rate of 23.1%, have the largest absolute number of potential patients, approximately 639 million [6] Group 3: Demographic Characteristics - Among demographic characteristics, the proportion of women meeting medication standards is 28.5%, higher than men's 25.5%, with the percentage increasing significantly with age, reaching 38.3% in the 55 to 64 age group [7] - Income and education levels correlate with medication eligibility, showing a contrasting trend in different economies: higher income correlates with higher eligibility in low and middle-income countries, while in high-income countries, lower-income groups have the highest eligibility [7] Group 4: Challenges and Recommendations - The study highlights the substantial theoretical and medical demand for GLP-1 receptor agonists in global obesity prevention and treatment, but real-world implementation faces significant challenges, particularly in middle-income countries where data on drug accessibility and usage is limited [7] - The high cost of these medications poses a barrier to widespread adoption in the short term, with uncertain long-term impacts on healthcare budgets [7] - The authors emphasize that GLP-1 receptor agonists should not be viewed as a singular solution to obesity; a multifaceted approach combining drug treatment with structural long-term strategies is necessary to address the global obesity epidemic [8]

Core Viewpoint - The weight loss drug market is experiencing significant growth due to the increasing global prevalence of overweight and obesity, with projections indicating that by 2035, over 4 billion people will be overweight or obese, and nearly 2 billion will suffer from obesity [3][4]. Group 1: Market Dynamics - The GLP-1 class of drugs has rapidly gained market traction, transforming obesity treatment from a conceptual model into a verifiable cash flow model [3][4]. - The market is shifting its focus from the effectiveness of weight loss to the feasibility of long-term use and the safety of prolonged medication [5][6]. Group 2: Health Implications - Weight loss does not equate to improved health, as studies show that significant muscle loss occurs alongside fat loss when using GLP-1 drugs, which can lead to adverse health outcomes [7][11]. - The loss of lean body mass, particularly skeletal muscle, is a critical concern, especially for older adults and those with pre-existing health conditions, as it can increase risks such as falls and metabolic decline [13][14]. Group 3: Future Directions in Drug Development - The next generation of weight loss drugs must address the issue of muscle preservation, as this will be essential for their acceptance as long-term treatment options [17][18]. - Two primary strategies are emerging: a replacement logic where new drugs outperform GLP-1 in fat loss while preserving muscle, and a combination logic where new drugs are used alongside GLP-1 to mitigate muscle loss [19][20]. Group 4: Target Populations - The combination of strong weight loss and muscle preservation is particularly relevant for severely obese patients with multiple comorbidities, as they are more likely to tolerate complex treatment regimens [23][25]. - In contrast, for lighter obese populations, the focus will shift to the quality of weight loss, emphasizing the importance of maintaining muscle mass during treatment [28][29]. Group 5: Industry Trends - The industry is witnessing a shift towards drugs that not only promote fat loss but also enhance muscle retention, with several companies actively pursuing this dual approach [32][33]. - The development of drugs with lower dosing frequencies aims to change the paradigm of obesity treatment from continuous medication to periodic maintenance, enhancing patient adherence and long-term outcomes [34].

Core Viewpoint - The article emphasizes the importance of hydration for individuals using GLP-1 medications for weight loss, highlighting that adequate water intake can enhance the efficacy of the drugs and mitigate side effects [5][7][8]. Group 1: Importance of Hydration - Water constitutes about 20% of daily total water intake from food, and using GLP-1 medications may lead to reduced food intake and potential dehydration risks [5] - Proper hydration is crucial for digestion and drug metabolism, ensuring sufficient digestive fluids are available to aid in food breakdown and nutrient absorption [7] - Insufficient water intake can lead to constipation and bloating, which may hinder weight loss efforts [7] Group 2: Symptoms of Dehydration - Users of GLP-1 medications may experience mild dehydration, leading to symptoms such as headaches, muscle cramps, nausea, constipation, fatigue, and dizziness [8] - Dehydration can exacerbate common gastrointestinal side effects of GLP-1, such as nausea and constipation, making hydration particularly important for those experiencing vomiting or diarrhea [8] Group 3: Detoxification and Fat Metabolism - Water aids in the elimination of toxins released from fat cells during weight loss, preventing their accumulation and ensuring effective metabolism [9] - Adequate hydration is necessary for the body to metabolize fat efficiently, as insufficient water can slow down weight loss progress [10] Group 4: Energy Levels and Exercise Performance - Fatigue is a common side effect of dehydration and weight loss medications; drinking water can help restore energy levels [12] - Hydration is essential for muscle function, endurance, and recovery, especially when exercise is part of a weight loss plan [12] Group 5: Hydration Guidelines - There are no specific guidelines for water intake for individuals using GLP-1 medications, but general recommendations suggest women should consume about 91 ounces and men about 125 ounces of water daily [13] - Individual hydration needs may vary based on factors such as body size, other medications, outdoor temperature, and physical activity [13] Group 6: Monitoring Hydration - A simple method to check hydration status is by observing urine color; light yellow indicates adequate hydration, while dark yellow suggests a need for increased intake [14] - Keeping track of fluid intake and ensuring regular hydration throughout the day can help meet daily liquid goals [14]

Core Viewpoint - The article discusses the discovery and potential of a new anti-obesity peptide called BRP (BRINP2-related peptide), which shows promise in reducing food intake and body weight without causing adverse effects such as nausea [7][12][14]. Group 1: Peptide Hormones and Their Role - Peptide hormones play a crucial role in regulating energy balance and appetite, making them ideal targets for obesity treatment [6]. - Over the past 40 years, scientists have identified 12 peptide substances involved in appetite regulation, but challenges remain in their discovery and functional characterization due to low abundance and difficulty in distinguishing active fragments from degradation products [6][9]. Group 2: Discovery of BRP - A significant study published by Stanford University utilized artificial intelligence to identify BRP, which effectively reduces food intake in mouse and pig models without causing nausea [7][12]. - BRP was found to activate the FOS protein in the central nervous system, independent of leptin, GLP-1 receptor, and melanocortin 4 receptor signaling pathways [7][12]. Group 3: Mechanism of Action - BRP's mechanism involves the activation of the CREB-FOS signaling pathway, which is crucial for its appetite-suppressing effects [20][22]. - The peptide was shown to induce significant phosphorylation of CREB and increase intracellular cAMP levels, indicating its action through Gαs-coupled GPCRs [20][22]. Group 4: Efficacy and Safety - In studies, BRP demonstrated a dose-dependent effect on food intake, with a 5 mg/kg dose significantly reducing consumption and a 20 mg/kg dose nearly completely suppressing it [12][13]. - Importantly, BRP did not affect animal activity, water intake, or induce aversive reactions, highlighting its potential as a safe weight-loss agent [13][14]. Group 5: Comparative Effectiveness - In pig models, BRP reduced food intake by 50% within one hour, showing effects comparable to GLP-1 receptor agonists like liraglutide [15]. - In obese mouse models, BRP treatment led to a significant reduction in body weight and fat mass without muscle loss, indicating its effectiveness in targeting fat reduction [17]. Group 6: Future Implications - The innovative methods used to identify BRP and its demonstrated efficacy suggest it could be a valuable therapeutic option for obesity treatment, potentially offering a new avenue for weight management without the side effects associated with current treatments [22].